Medical Developments International Limited · ASX:MVP
Medical Developments International — Non-Deal Roadshow (February 2016)
24 slides from Medical Developments International's roadshow presentation, Feb 5, 2016
Slide 1: Medical Developments International UK Road Show
Medical Developments International UK Road Show - 4th & 5th February 2016
Slide 2: Vision
Vision Medical Developments International (MDI) is a leading Emergency Medicine Company. Our aim is to: 1. Dominate the analgesic trauma and minor surgical procedures market domestically and internationally. 2. Dominate the Respiratory Medical Devices market domestically and internationally. 3. Prov
Slide 3: Vision
Vision MDI is working on and delivering two “company making” business opportunities. The risk profile of these opportunities is relatively low and well understood. Penthrox: Our regulatory initiatives, already successful, are transforming the company. Penthrox has the potential to be the market lead
Slide 4: Penthrox: A world class opportunity
Penthrox A world class opportunity Penthrox® • Market Leader for trauma pain • Inhalational analgesic • Demonstrated safety and efficacy profile • Only manufacturer in the world • Sold in Australia, N.Z, GCC, UK, Europe, South America, Eastern Europe & others • Manufactured in GMP compliant plant
Slide 5: Penthrox: A world class opportunity
Penthrox A world class opportunity • Significant competitive advantages to other analgesics. • Fast, safe, rapid on-set, effective, cost-competitive, self administered. • No needles, non-opiate, non addictive, easy to store & transport. • Built world class regulatory dossier and using it to achieve
Slide 6: Penthrox Clinical application
Penthrox Clinical application Painful procedures • Burn injuries Cosmetic Dentistry Surgery • Cutaneous excisions • Breaks, • Liquid nitrogen fractures and Military Consulting removals of skin- dislocations Rooms cancers, warts, etc • Abdomen pain • Invasive • Chest pain Ambulance Day Surgeries angi
Slide 7: Benefits to medical professionals
Penthrox Benefits to medical professionals Rapid onset of Minimal waiting time before a painful procedure can be performed action (3 minutes) and rapid pain relief when a patient is treated for burns, trauma, etc. Inhaled self- Medical professionals can perform a procedure/attend to an injury admini
Slide 8: Benefits over Nitrous Oxide
Penthrox Benefits over Nitrous Oxide The benefits of using Penthrox® over Nitrous Oxide include: • Penthrox does not effect vital signs; no clinical depression of respiration or circulation. • Penthrox is self-administered and easy to use. • Penthrox is compact and can be used in any location or sit
Slide 9: Benefits over Morphine
Penthrox Benefits over Morphine The benefits of using Penthrox® over Morphine are the same as detailed for Nitrous. In addition there are a number of specific benefits Penthrox has over Morphine which include: • Penthrox does not effect vital signs; no clinical depression of respiration or circulati
Slide 10: Penthrox Manufacturing
Penthrox Manufacturing MDI has signed a deal with CSIRO and developed a new manufacturing technique for Penthrox. MDI now has: 1. World leading intellectual property. 2. Very significant increased production capacity. 3. Very significant reduction in cost to manufacture. 4. Very significant competit
Slide 11: Penthrox Future
Penthrox Future MDI has spent more than $10 million on developing a regulatory dossier capable of getting Penthrox approved for sale in other countries. We have achieved significant regulatory approvals in Europe and elsewhere during 2015. MDI is working on regulatory approvals to expand into new co
Slide 12: Penthrox Future: global trauma market sales opportunity
Penthrox Future Indication of the size of the Penthrox sales opportunity in the global trauma market Penthrox potential sales AUD million Europe Sales in excess of $300 North America Sales in excess of $800 Latin America Sales in excess of $250 Asia Sales in excess of $500
Slide 13: Penthrox Future
Penthrox Future Our plan is to use the Regulatory dossier to improve the positioning and obtain approvals to sell Penthrox around the world. We are developing new Penthrox products and have registered patent applications which will deliver IP protection. We have developed a new manufacturing methodo
Slide 14: Penthrox Future: additional markets
Penthrox Future In addition to the global trauma market, MDI has plans to develop applications for its products in the following markets: • Minor Surgical Procedure • Military • Home Use trauma • World Aid (no needles, opioid's or infection)
Slide 15: MDI Medical Respiratory division
MDI Medical Respiratory division MDI has a long history of investing R&D resources to design and improve respiratory devices used to deliver Asthma and COPD medication. In 2011 MDI launched a new range of products using MDI’s Cross Valve TechnologyTM, a patented system of drug delivery which ensures
Slide 16: MDI Medical Respiratory division
MDI Medical Respiratory division MDI offers a range of devices that can be used to help patients manage and take control of their asthma and COPD. • Space Chamber Plus® anti-static range • Space Chamber Plus® aerosol spacer • Space Chamber® re-usable • Compact Spacer Chamber Plus® • Breath-Alert® pe
Slide 17: MDI Medical Respiratory division
MDI Medical Respiratory division Recently approved by the FDA for sale in the USA. Recently registered by MHRA for full reimbursement. New distribution partners. Growing business internationally. MDI now has business and is making sales in: Australia, UK, Singapore, Hong Kong, Canada, Malaysia, Belg
Slide 18: Respiratory division Future
Respiratory division Future MDI is investing heavily in developing new and innovative products • Anti static spacers • Anti static mask – (1st of its kind) • Electronic peak flow • Smart phone asthma & COPD applications
Slide 19: MDI Corporate Overview
MDI Corporate Overview MDI has three business divisions. Pharmaceutical Medical devices Veterinary MDI has been profitable every year since listing on the ASX in 2003 and: • has generated a positive cash flow every year; • pays tax and has paid fully franked dividends; • has received almost $1
Slide 20: MDI Corporate Overview: Board and Management Team
MDI Corporate Overview David Williams Dr Harry Oxer Leon Hoare Max Johnston Allan McCallum Phillip Powell Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Chairman Director Director Director Director Director The Managing A Medical Consultant The Managing A Non-Exe
Slide 21: MDI Global strategy
MDI Global strategy Our aim is to: 1. Dominate the analgesic trauma and minor surgical procedures market domestically and internationally. 2. Dominate the Respiratory Medical Devices market domestically and internationally.
Slide 22: MDI Global strategy
MDI Global strategy New and revised materials and process (lowest cost producer and significant IP) New Business Partners Product innovation (worlds best delivery devices and significant IP) Clinical trials (Commercial clinical studies to support marketing and Regulatory product development) Approva
Slide 23: Contact details
Contact details HEAD OFFICE 4 Caribbean Drive Scoresby VIC 3179 Tel: +61 3 9547 1888 Fax: +61 3 9547 0262 Web: www.medicaldev.com
Slide 24: Forward looking statements
Forward looking statements This document contains certain forward looking statements relating to Medical Development International’s business, which can be identified by the use of forward looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast", "exp
Medical Developments International — Non-Deal Roadshow (February 2016) on 6ix